Diabetes is the result of having inadequate supply of functional insulin-producing β cells.
Two possible approaches for replenishing the β cells are:(1) replacement by transplanting …

Insulin therapy became a reality in 1921 dramatically saving lives of people with diabetes,
but not protecting them from long-term complications. Clinically successful free islet implants …

The transplantation of pancreatic islet cells could restore glycaemic control in patients with
type 1 diabetes. Microspheres for islet encapsulation have enabled long-term glycaemic …

Macroscale drug delivery (MDD) devices are engineered to exert spatiotemporal control
over the presentation of a wide range of bioactive agents, including small molecules …

In type 1 diabetes (T1D) β cell mass is markedly reduced by autoimmunity. Type 2 diabetes
(T2D) results from inadequate β cell mass and function that can no longer compensate for …

The achievements of cell-based therapeutics have galvanized efforts to bring cell therapies
to the market. To address the demands of the clinical and eventual commercial-scale …

Type 1 diabetes mellitus (T1DM) is the most common chronic autoimmune disease in young
patients and is characterized by the loss of pancreatic β cells; as a result, the body becomes …

Type 1 diabetes (T1D) is caused by autoimmune destruction of insulin-producing β cells
located in the endocrine pancreas in areas known as islets of Langerhans. The current …

Type 1 diabetes mellitus (T1DM) is a chronic metabolic disease caused by the destruction of
pancreatic β‐cells in response to autoimmune reactions. Shapiro et al. conducted novel islet …

For the past century, insulin injections have saved millions of lives, but glycemic instability is
still a persistent challenge for people with diabetes, leading to tremendous morbidity and …